CHARACTERIZATION AND DESCRIPTION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE ASSESSED BY HEPATIC ELASTOGRAPHY IN A CENTER IN BOGOTA

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-09-01 DOI:10.1016/j.aohep.2025.102029

Lina Marcela Dorado Delgado , Laura Cristina Arocha Dugand , Martin Alonso Garzón Olarte , Danna Lesley Cruz Reyes , Nicole Guzmán , Oscar Beltrán , Geovanny Hernández , Carolina Salinas , Cristina Torres , Adriana Varón Puerta

{"title":"CHARACTERIZATION AND DESCRIPTION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE ASSESSED BY HEPATIC ELASTOGRAPHY IN A CENTER IN BOGOTA","authors":"Lina Marcela Dorado Delgado , Laura Cristina Arocha Dugand , Martin Alonso Garzón Olarte , Danna Lesley Cruz Reyes , Nicole Guzmán , Oscar Beltrán , Geovanny Hernández , Carolina Salinas , Cristina Torres , Adriana Varón Puerta","doi":"10.1016/j.aohep.2025.102029","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disease globally, with 25–30% of patients progressing to fibrosis. It is associated with complications such as cirrhosis, liver failure, and liver cancer. Transient liver elastography (TLE) is a non-invasive, reliable tool to assess hepatic steatosis and fibrosis, with lower risk than biopsy. This study aims to characterize patients with MASLD at Fundación Cardioinfantil by analyzing demographic and clinical factors, and the grade of liver steatosis and fibrosis using TLE</div></div><div><h3>Materials and Methods</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disease globally, with 25–30% of patients progressing to fibrosis. It is associated with complications such as cirrhosis, liver failure, and liver cancer. Transient liver elastography (TLE) is a non-invasive, reliable tool to assess hepatic steatosis and fibrosis, with lower risk than biopsy. This study aims to characterize patients with MASLD at Fundación Cardioinfantil by analyzing demographic and clinical factors, and the grade of liver steatosis and fibrosis using TLE</div></div><div><h3>Results</h3><div>In the interim analysis of 899 patients, elastography results met international quality standards (IQR/M 18.3). The average BMI was 27.2 kg/m<sup>2</sup>, and common comorbidities included hypertension and diabetes. Steatosis was typically moderate (LiSA S2), with a higher LiSA score in those with higher BMI (graphic 1). Fibrosis was absent in 78.3% of cases, while 21.7% showed progression (table 1) of this population 69.9% have overweight or obesity.</div></div><div><h3>Conclusions</h3><div>MASLD is primarily associated with metabolic diseases. This study found that higher BMI is linked to an increased risk of steatosis, and higher levels of fibrosis were seen in older patients (with no linear relationship). These patients should be prioritized for early screening and treatment, reducing complications and overall morbidity and mortality.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 102029"},"PeriodicalIF":4.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268125002546","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objectives

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disease globally, with 25–30% of patients progressing to fibrosis. It is associated with complications such as cirrhosis, liver failure, and liver cancer. Transient liver elastography (TLE) is a non-invasive, reliable tool to assess hepatic steatosis and fibrosis, with lower risk than biopsy. This study aims to characterize patients with MASLD at Fundación Cardioinfantil by analyzing demographic and clinical factors, and the grade of liver steatosis and fibrosis using TLE

Materials and Methods

Results

In the interim analysis of 899 patients, elastography results met international quality standards (IQR/M 18.3). The average BMI was 27.2 kg/m², and common comorbidities included hypertension and diabetes. Steatosis was typically moderate (LiSA S2), with a higher LiSA score in those with higher BMI (graphic 1). Fibrosis was absent in 78.3% of cases, while 21.7% showed progression (table 1) of this population 69.9% have overweight or obesity.

Conclusions

MASLD is primarily associated with metabolic diseases. This study found that higher BMI is linked to an increased risk of steatosis, and higher levels of fibrosis were seen in older patients (with no linear relationship). These patients should be prioritized for early screening and treatment, reducing complications and overall morbidity and mortality.

查看原文本刊更多论文

波哥大某中心肝脏弹性成像评估代谢功能障碍相关脂肪变性肝病的特征和描述

代谢功能障碍相关脂肪变性肝病（MASLD）是全球最常见的肝脏疾病，25-30%的患者进展为纤维化。它与肝硬化、肝功能衰竭和肝癌等并发症有关。瞬时肝弹性成像（TLE）是一种评估肝脏脂肪变性和纤维化的无创、可靠的工具，其风险低于活检。本研究旨在通过分析人口统计学和临床因素来表征Fundación Cardioinfantil的MASLD患者，并使用le分析肝脏脂肪变性和纤维化的等级。材料和方法代谢功能障碍相关的脂肪变性肝病（MASLD）是全球最常见的肝脏疾病，25-30%的患者进展为纤维化。它与肝硬化、肝功能衰竭和肝癌等并发症有关。瞬时肝弹性成像（TLE）是一种评估肝脏脂肪变性和纤维化的无创、可靠的工具，其风险低于活检。本研究旨在通过分析人口统计学和临床因素，以及使用tlerr分析肝脂肪变性和纤维化的分级来表征Fundación Cardioinfantil的MASLD患者。结果在899例患者的中期分析中，弹性成像结果符合国际质量标准（IQR/M 18.3）。平均BMI为27.2 kg/m2，常见合并症包括高血压和糖尿病。脂肪变性通常为中度（LiSA S2）， BMI越高，LiSA评分越高（图1）。78.3%的病例没有纤维化，而21.7%的患者有进展（表1），69.9%的患者超重或肥胖。结论smasld主要与代谢性疾病相关。该研究发现，较高的BMI与脂肪变性风险增加有关，老年患者的纤维化水平较高（没有线性关系）。这些患者应优先进行早期筛查和治疗，减少并发症和总体发病率和死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.